Results 1 to 10 of about 2,655 (107)

Immunotherapy of cancer in 2012

Ca-A Cancer Journal for Clinicians, 2012
Ahmad A Tarhini, Lisa H Butterfield
exaly  

Novel Agents on the Horizon for Cancer Therapy

Ca-A Cancer Journal for Clinicians, 2009
exaly  

[Further clinical research on a new anticholesteremic agent (4-diphenylyl ethyl-acetic acid)].

La Clinica terapeutica, 2000
openaire   +1 more source

[Regression and therapy of atherosclerosis: drug therapy of atherosclerosis viewed from serum lipoprotein analysis--reality of application, choice and administration of anticholesteremic agents].

Nihon rinsho. Japanese journal of clinical medicine, 1988
openaire   +1 more source

Targeting Apoptosis Pathways in Cancer Therapy

Ca-A Cancer Journal for Clinicians, 2005
exaly  

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

Ca-A Cancer Journal for Clinicians, 2013
exaly  

Immunosurveillance in clinical cancer management

Ca-A Cancer Journal for Clinicians
Lorenzo Galluzzi
exaly  

Lymphedema: A primer on the identification and management of a chronic condition in oncologic treatment

Ca-A Cancer Journal for Clinicians, 2009
exaly  

Chronic Inflammation: A Common and Important Factor in the Pathogenesis of Neoplasia

Ca-A Cancer Journal for Clinicians, 2006
exaly  

Assessing Prescribing Patterns of Nonstatins as Add-on Therapy for Secondary Prevention in a Federally Qualified Health Center [PDF]

Pharmacy
Background: Lipid management is a key aspect of secondary atherosclerotic cardiovascular disease (ASCVD) prevention. However, real-world studies show that ~72–88% of patients with ASCVD fail to meet their low-density lipoprotein cholesterol (LDL-C ...
Sabrina Guerra, Kathryn P. Lin, Ahmed S. Kenawy, Chanhyun Park, Morgan P. Stewart   +4 more
doaj   +2 more sources